Tác động đến sự hài lòng và mức độ tham gia dịch vụ của Paliperidone Palmitate so với Paliperidone đường uống ở bệnh nhân tâm thần phân liệt: Một thử nghiệm kiểm soát ngẫu nhiên mở

Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophrenia Bullettin. 2013;39:1363–72. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–41. Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2015. https://doi.org/10.1016/j.pnpbp.2014.11.006. Warner R. Recovery from schizophrenia and the recovery model. Curr Opin Psychiatry. 2009;22(4):374–80. Pietrini F, Spadafora M, Tatini L, Talamba GA, Andrisano C, Boncompagni G, Manetti M, Ricca V, Ballerini A. LAI versus oral: a case–control study on subjective experience of antipsychotic maintenance treatment. Eur Psychiatry. 2016;37:35–42. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18(13):877–93. Haro JM, Salvador-Carulla L. The Schizophrenia outpatient health outcome(SOHO) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20(4):293–301. Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311–7. Gharabawi GM, Greenspan A, Rupnow M. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CULASS 1). Arch Gen Psychiatry. 2006;63(10):1079–87. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336–46. Yang F, Li J, Tan YL, Liang WY, Zhang R, Wang N, Feng W, Cai S, Zhuo JM, Zhang LL. Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication. Neuropsychiatr Dis Treat. 2017. https://doi.org/10.2147/ndt.s130483. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932–9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 10. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23. Erratum in: N Engl J Med. 2010;363(11):1092–3. Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. https://doi.org/10.1007/s40263-016-0350-7. Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30(6):320–8. Schreiner A, Caspi A, Bergmans P, Cherubin P, Keim S, Lara E, Pinchuk I, Schuepbach D, Suleman S, Hargarter L. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study. Psychopharmacology (Berl). 2017;234(1):3–13. Isitt JJ, Nadipelli VR, Kouassi A, Fava M, Heidbreder C. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016;174(1–3):126–31. Bradley GM, Couchman GM, Perlesz A, Nguyen AT, Singh B, Riess C. Multiple-family group treatment for English- and Vietnamese-speaking families living with schizophrenia. Psychiatr Serv. 2006;57(4):521–30. Roeg D, van de Goor I, Garretsen H. Predicting initial client engagement with community mental health services by routinely measured data. Community Ment Health J. 2015;51(1):71–8. Boudreaux JG, Crapanzano KA, Jones GN, Jeider TA, Dodge VH, Hebert MJ, Kasofsky JM. Using mental health outreach teams in the emergency department to improve engagement in treatment. Community Ment Health J. 2016;52(8):1009–14 Rossi A, Galderisi S, Rocca P, Bertolino A, Mucci A, Rucci P, Gibertoni D, Aguglia E, Amore M, Andriola I, Bellomo A, Biondi M, Callista G, Comparelli A, Dell’Osso L, Di Giannantonio M, Fagiolini A, Marchesi C, Monteleone P, Montemagni C, Niolu C, Piegari G, Pinna F, Roncone R, Stratta P, Tenconi E, Vita A, Zeppegno P, Maj M, Italian Network for Research on Psychoses. The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. Eur Arch Psychiatry Clin Neurosci. 2017;267(4):285–94. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–17. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685–97. Mauri M, Mauri MC, Adami M, Reggiardo G, Giulio C. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach. Int Clin Psychopharmacol. 2015;30(6):329–37. Mauri MC, Reggiori A, Paletta S, Di Pace C, Altamura AC. Paliperidone for the treatment of schizophrenia and schizoaffective disorders—a drug safety evaluation. Expert Opin Drug Saf. 2017;16(3):365–79. Chen CY, Tang TC, Chen TT, Bai YM, Tsai HH, Chen HL, Huang CJ, Chen CK, Chen CC, Hsiao MC, Liu CY, Yeh HS, Chiu NY, Hsiao CC, Chen CS, Su TP. Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan. Neuropsychiatr Dis Treat. 2018;14:725–32. Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, García-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018;33(1):15–33. https://doi.org/10.1097/YIC.0000000000000195. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol. 2010;25(6):334–41. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;26(2):12. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(Suppl 3):133–8. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88. Erratum in: Schizophr Res. 2002;57(1):125. Rajonk F [corrected to Pajonk FG]. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. J Ment Health. 2002;11(2):191–8. Guy W. ECDEU Assessment Manual for Psychopharmacology. Clinical Global Impressions. Rockville: National Institute for Mental Health; 1976. p. 218–22. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodríguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB, SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;416:16–23. Marchiaro L, Rocca P, LeNoci F, Longo P, Montemagni C, Rigazzi C, Bogetto F. Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. J Clin Psychiatry. 2005;66(11):1423–31. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9. Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. Int Clin Psychopharmacol. 2016;31(6):315–22. Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophr Res. 2018;192:185–93. Liu M, Liu X, Miao X, Gao X. Effects of paliperidone extended-release tablets and risperidone on cognitive function in patients with first-episode schizophrenia. Chin J New Drugs. 2012;21(4):419–22. Suzuki H, Inoue Y, Mikami K, Gen K. The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer’s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial. Int J Psychiatry Clin Pract. 2014;4(1):37–42. Chen F, Zhou H, Lu Z. Cognitive effect of flexible-dose oral paliperidone extended-release tablets in treating acute schizophrenia. Chin J New Drugs. 2012;21(19):2297–301. Shi C, Yu X, Kang L, et al. Paliperidone ER treatment and the improvement of social and cognitive function in patients with schizophrenics—a 24-week, single arm, open-label study. Schizophr Res. 2014;153(Suppl 1):S118. Shi C, Yao SQ, Xu YF, Shi JG, Xu XF, Zhang CP, Jin H, Yu X. Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study. Neuropsychiatr Dis Treat. 2016;24(12):2095–104. Takekita Y, Koshikawa Y, Sakai S, Sunada N, Onohara A, Nishida K, Yoshimura M, Kato M, Serretti A, Kinoshita T. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry. 2016;16:172. Zhang L, Li J, Zhao Y, Su Y, Si T. Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatr Dis Treat. 2016;11(12):113–31. Kane J. Progress defined—short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol. 2001;16(Suppl 1):S1–8. Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27(8):625–36. Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–9. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197(6):448–55. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–29. Adams T. The conversational and discursive construction of community psychiatric nursing for chronically confused people and their families. Nurs Inq. 2001;8(2):98–107. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–9. Kim SW, Lee YH, Jang JE, Yoo T, Kim JM, Shin IS, Yoon JS. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients. Int Clin Psychopharmacol. 2013;28(2):80–6. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(Suppl 1):38–52. Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case–control study. Int Clin Psychopharmacol. 2013;28(4):164–70. Schreiner A, Svensson A, Wapenaar R, Cherubin P, Princet P, Serazetdinova L, Zink M. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). World J Biol Psychiatry. 2014;15(7):534–45. Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10(5):365–77. Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, Bitter I, Bilanakis N, Schreiner A. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043–53. Schreiner A, Bergmans P, Cherubin P, Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Ther Adv Psychopharmacol. 2017;7(2):59–65. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169(2):97–100. Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16(1):31–43.